BMEA (Biomea Fusion Inc) רווח למניה בארבעת הרבעונים האחרונים

Biomea Fusion, Inc. (BMEA) focuses on the therapy of metabolic disorders and oncology. Scientific partnerships with universities help the company restore cellular functions. This daily price chart reflects the earnings per share, which stands at 86.70. Proprietary patents for menin inhibitors and strict FDA oversight block competitors from entering the niche. Meanwhile, a portion of the research is delegated to external laboratories without the loss of intellectual property rights.
BMEA (Biomea Fusion, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

An issuer's long-term reliability is determined by its ability to consistently grow earnings per share. This metric measures the annual growth rate of profit, allowing for an assessment of the business's capitalization efficiency. By analyzing the EPS YoY percentage change over 12 months, an investor can see the real dynamics of value creation. For Biomea Fusion, Inc. (BMEA), which is in the clinical trial stage without current revenues, this indicator confirms the company's dependence on external financing.